Secondary Prevention of Ischemic Stroke in Urban China

被引:85
|
作者
Wei, Jade W. [1 ]
Wang, Ji-Guang [2 ]
Huang, Yining [3 ]
Liu, Ming [4 ]
Wu, Yangfeng [5 ]
Wong, Lawrence K. S. [6 ]
Cheng, Yan [7 ]
Xu, En [8 ]
Yang, Qidong [9 ]
Arima, Hisatomi [1 ]
Heeley, Emma L. [1 ]
Anderson, Craig S. [1 ]
机构
[1] Royal Prince Alfred Hosp, George Inst Int Hlth, Camperdown, NSW 2050, Australia
[2] Shanghai Jiao Tong Univ, Ctr Epidemiol Studies & Clin Trials, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
[3] Peking Univ, Hosp 1, Dept Neurol, Beijing 100871, Peoples R China
[4] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, George Inst China, Beijing 100871, Peoples R China
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[7] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
[8] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
[9] Ctr S Univ, Xiangya Hosp, Changsha, Peoples R China
关键词
China; prevention; stroke; 1ST-EVER STROKE; ATTACK; INTERVENTION; GUIDELINES; ADHERENCE; VALIDITY; HISTORY; CARE;
D O I
10.1161/STROKEAHA.109.571463
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We aimed to describe the uptake of proven secondary prevention strategies for ischemic stroke in urban China. Methods-In a prospective, multicenter, hospital-based registry of 4782 cases of acute ischemic stroke in China during 2006, the use of secondary prevention regimens was evaluated before hospital discharge and 3 and 12 months after stroke. Logistic regression analysis was performed to determine associations between various baseline variables and in-hospital use of antihypertensive, antiplatelet, and lipid-lowering therapies, and to identify variables associated with their continuation at 12 months. Results-In-hospital initiation of antihypertensive (63%), antiplatelet (81%), and lipid-lowering (31%) therapies was influenced favorably by previous use and comorbid cardiovascular risk factors and unfavorably by stroke severity. Antihypertensive use was well-maintained during follow-up, whereas use of antiplatelet and lipid-lowering therapy decreased (66% and 17%, respectively; P<0.001) by 12 months after stroke, with discontinuation related to patient and physician factors. Interpretation-There was a high level of uptake of secondary prevention for ischemic stroke in this nationwide sample of hospitalized patients in urban China. However, use of antiplatelet and lipid-lowering therapy declined substantially after discharge, apparently related to misperceptions of subsequent disease risk by both doctors and patients. (Stroke. 2010;41:967-974.)
引用
收藏
页码:967 / 974
页数:8
相关论文
共 50 条
  • [31] Antiplatelet medications in the secondary prevention of ischemic stroke
    James D. Fleck
    Current Neurology and Neuroscience Reports, 2005, 5 (1) : 1 - 3
  • [32] WARFARIN OR ASPIRIN AS SECONDARY PREVENTION OF ISCHEMIC STROKE
    CHIMOWITZ, MI
    CNS DRUGS, 1994, 2 (05) : 341 - 346
  • [33] Update on antithrombotic secondary prevention of ischemic stroke
    Koehrmann, Martin
    Kleinschnitz, Christoph
    NERVENARZT, 2019, 90 (10): : 995 - 1004
  • [34] Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China
    Jiang, Yue
    Yang, Xiaomeng
    Li, Zixiao
    Pan, Yuesong
    Wang, Yilong
    Wang, Yongjun
    Ji, Ruijun
    Wang, Chen
    NEUROLOGICAL RESEARCH, 2017, 39 (06) : 492 - 497
  • [35] Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
    Davis, Stephen M.
    Donnan, Geoffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20): : 1914 - 1922
  • [36] Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
    Bangalore, Sripal
    Schwamm, Lee
    Smith, Eric E.
    Singh, Inder M.
    Liang, Li
    Fonarow, Gregg C.
    Bhatt, Deepak L.
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (08): : 728 - 738
  • [37] Antiplatelets for secondary stroke prevention in China
    Wu, Simiao
    Anderson, Craig S.
    LANCET NEUROLOGY, 2023, 22 (06): : 457 - 459
  • [38] Implementation of a Structured Guideline-Based Program for the Secondary Prevention of Ischemic Stroke in China
    Peng, Bin
    Ni, Jun
    Anderson, Craig S.
    Zhu, Yicheng
    Wang, Yongjun
    Pu, Chuanqiang
    Wu, Jiang
    Wang, Jianming
    Zhou, Lixin
    Yao, Ming
    He, Jia
    Shan, Guangliang
    Gao, Shan
    Xu, Weihai
    Cui, Liying
    STROKE, 2014, 45 (02) : 515 - 519
  • [39] Evaluation on the compliance with secondary prevention and influence factors of ischemic stroke in Hainan province, China
    Su, Qingjie
    Yuan, Kunxiong
    Long, Faqing
    Wan, Zhongqin
    Li, Chaoyun
    Cai, Yi
    Zeng, Chaosheng
    Wu, Yingman
    Wu, Hairong
    Liu, Shu
    Li, Pengxiang
    Zhou, Jingxia
    Chen, Cong
    Wang, Desheng
    Yan, Limin
    Zhang, Yuhui
    Dai, Mingming
    VASCULAR, 2014, 22 (03) : 181 - 187
  • [40] Antiplatelet treatment for secondary prevention of ischemic stroke or transient ischemic attack
    Barinagarrementeria, Fernando
    Arauz, Antonio
    Luis Ruiz-Sandoval, Jose
    Cantu, Carlos
    Leyva, Adolfo
    Murillo, Luis
    Villarreal, Jorge
    Dario Vargas, Ruben
    Antonio Alegria, Marco
    Merino, Jose G.
    Romano, Jose
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2010, 62 (02): : 135 - 140